AgeX Therapeutics Receives $4.5 Million From Exercise of Warrants
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar 22, 2019--AgeX Therapeutics, Inc. (“AgeX”, NYSE American: AGE), a biotechnology company focused on innovative therapeutics for human aging, announced today that it has received $4.5 million from the exercise of AgeX common stock warrants. Warrant holders purchased a total of 1,800,000 shares of AgeX common stock through the exercise of warrants at an exercise price of $2.50 per share. The warrants were issued to investors by AgeX during 2018. Any warrants that were not exercised have expired.
Additional details may be found in AgeX’s Form 8-K filed with the Securities and Exchange Commission on March 22, 2019.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem ® and UniverCyte ™ manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a whole host of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX’s revolutionary longevity platform named induced Tissue Regeneration (iTR™) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem ® is AgeX’s delivery technology to stably engraft PureStem cell therapies and slowly release iTR molecules in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan, and is seeking opportunities to form licensing and partnership agreements around its broad IP estate and proprietary technology platforms for non-core clinical applications.
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the “Risk Factors” section of AgeX’s Information Statement filed as an exhibit to its Registration Statement on Form 10 with the Securities and Exchange Commissions (copies of which may be obtained at www.sec.gov ). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190322005107/en/
CONTACT: Media Contact for AgeX:Bill Douglass
Gotham Communications, LLC
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: SENIORS STEM CELLS HEALTH BIOTECHNOLOGY CARDIOLOGY MEDICAL DEVICES PHARMACEUTICAL RESEARCH DIABETES CONSUMER SCIENCE
SOURCE: AgeX Therapeutics, Inc.
Copyright Business Wire 2019.
PUB: 03/22/2019 07:00 AM/DISC: 03/22/2019 07:00 AM